Position in SVTR
Snapshot 2026-11-03- Startup SignalsRankedof 2,280↓30
- Life SciencesRankedof 239–
- AI for ScienceRankedof 113–
- Drug DiscoveryRankedof 67–
About
Latent Labs, founded in 2023 in London and San Francisco, develops generative AI models designed to capture fundamental principles of biology for drug discovery and genetic engineering.
Technology & BusinessWhat · How · Which stage
Research AreasLife SciencesBiologyMediumEvidence
开发生成性人工智能模型，帮助创造新抗体、优化酶并推进基因工程
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2025-02Series A$40M
Investors · Pillar VC, Sofinnova Partners, Flying Fish Ventures, Radical Ventures, Kindred Ventures, Isomer, 8VCSource · SVTR Weekly #092 ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Latent Labs
Generative AI models to create new antibodies, optimize enzymes and advance genetic engineering
Series A · $40M · 2025-02
$40M
United States
BusinessLatest roundTotal raisedDate- Ten63 Therapeutics
Applies generative AI models to drug discovery and development
$54M · 2026-03
$54M - Unnatural Products
Combines AI and chemistry to create new drugs, particularly synthetic drugs mimicking natural macrocycles
Undisclosed · $32M · 2023-12
$32M - Terray Therapeutics
Combines AI with wet lab science to discover new small-molecule drugs
Undisclosed · $120M · 2024-10
$120M
China
BusinessLatest roundTotal raisedDate- BioGeometry
Generative AI protein/antibody design platforms (GeoFlow, GeoBiologics) and closed-loop dry-wet lab drug discovery
Series A · $100M · 2026-10
$100M - Drug Farm
Drug developer using genetics and AI to discover first-in-class targets
Series D+ · $55M · 2026-07
$55M - Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M
Europe
BusinessLatest roundTotal raisedDate- Cradle
AI that helps scientists design and engineer proteins faster and more cost-effectively
Undisclosed · $106M · 2024-12
$106M - Healx
AI to discover and develop treatments for rare diseases
Undisclosed · $47M · 2024-08
$47M - Alchemab Therapeutics
AI-based discovery and development of therapeutic antibodies from "naturally resistant" populations
Series A · $32M · 2025-09
$32M
Other / unspecified
BusinessLatest roundTotal raisedDate- Altis Labs
AI imaging biomarker platform across solid tumor types and therapeutic areas
Series A · $31M · 2026-09
$31M - Mana.bio
Uses AI to design lipid nanoparticles for delivering mRNA to specific parts of the body
Seed · $20M · 2023-10
$20M - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Related coverage
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 34 at a nearby stage · 32 in Silicon Valley
Request intro →General Catalyst
38 Life Sciences deals in the last 24 months · 24 at a nearby stage · 34 in Silicon Valley
Request intro →Andreessen Horowitz
22 Life Sciences deals in the last 24 months · 11 at a nearby stage · 20 in Silicon Valley
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in Silicon Valley
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 15 in Silicon Valley
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 10 at a nearby stage · 14 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.